A Phase 1/2 interventional study of cemiplimab (monotherapy) and cemiplimab (maintenance) in Relapsed Solid Tumor, Refractory Solid Tumor and Relapsed Central Nervous System Tumor, sponsored by Regeneron Pharmaceuticals. Terminated at 20 sites in United States. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States — 23 open to participants now, 34 under way, none of them phase 3. Diffuse Intrinsic Pontine Glioma · United States.
Among the 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States, this one is the 22nd largest by enrollment of the 82 interventional ones that give a count, is one of 9 that started in 2018, is one of 17 in phase 1/2, and was the 46th registered.
119 studies on the registry are indexed under Diffuse Intrinsic Pontine Glioma; 38 are open to participants now.
Browse Diffuse Intrinsic Pontine Glioma studies →23 of the 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States are open now. Recruiting first, the newest first:
BrainChild Bio, Inc · Sites in United States
Ages 1–26
Children's National Research Institute · Sites in United States
Ages 3–25
Milton S. Hershey Medical Center · Sites in United States
Ages up to 26
M.D. Anderson Cancer Center · Sites in United States
Ages 36 mo+
Nationwide Children's Hospital · Sites in United States, Australia, Canada and 3 more countries
Ages 1–21 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Diffuse Intrinsic Pontine Glioma studies recruiting now, 3 (11%) set no upper age limit and 25 (89%) stop at 75 or younger; 27 take children under 18; 2 take healthy volunteers.
This study: Up to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 63 · Phase 2 32
First in 2002; this study’s year is marked. 9 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is above the median of 30 across 109 interventional studies indexed under Diffuse Intrinsic Pontine Glioma.
Median enrollment 30 across the 82 interventional studies, 100 across the 5 observational. Of the 47 that completed or were terminated, 17 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 88 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 1 study filed under Diffuse Intrinsic Pontine Glioma — fewer than ten, so there is no comparison to draw.
9 of the studies in Diffuse Intrinsic Pontine Glioma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05762419Columbia UniversityFUS Etoposide for DMG | 2026-12 |
| NCT04655404Nationwide Children's HospitalA Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | 2026-12-01 |
| NCT04870944Children's Oncology GroupCBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | 2026-12-31 |
| NCT04099797Baylor College of MedicineC7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | 2027-02 |
| NCT01837862Julie KrystalA Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | 2027-03 |
Add all 9 to your calendar (.ics) → With an account.
Among the 88 studies in Diffuse Intrinsic Pontine Glioma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1:
Phase 2 (Efficacy Phase):
119 studies on the registry are indexed under Diffuse Intrinsic Pontine Glioma; 38 are open to participants now.
This study's enrollment of 57 is above the median of 30 across 109 interventional studies indexed under Diffuse Intrinsic Pontine Glioma.
Browse Diffuse Intrinsic Pontine Glioma studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Compared within Diffuse Intrinsic Pontine Glioma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Central Nervous System Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in both the Solid Tumor Cohort and the CNS Cohort will receive cemiplimab monotherapy. Each Cohort will have 2 subgroups by age (0 to \<12 years, 12 to \<18 years).
Drug: cemiplimab (monotherapy)
≥ 3 to \< 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
Drug: cemiplimab (maintenance) · Radiation: Conventional or hypofractionated
≥ 3 to \< 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
Drug: cemiplimab (maintenance) · Radiation: Conventional or hypofractionated
≥ 3 to \< 12 years cohort and 12 to ≤ 25 years cohort with combination of cemiplimab and radiation therapy
Drug: cemiplimab (maintenance) · Radiation: Re-irradiation
To be administered intravenously as monotherapy in Phase 1
Also known as: REGN2810, Libtayo
To be administered intravenously in combination with radiation and then used as maintenance therapy
Also known as: REGN2810, Libtayo
Combined with cemiplimab IV administration
Combined with cemiplimab IV administration
Number of Treatment-emergent Adverse Events (TEAEs)
TEAEs are AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occur during the post-treatment period but prior to initiation of other anticancer therapy. Number of TEAEs reported.
Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Number of Severe (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade 3/4/5) TEAEs
NCI CTCAE version 4.0 was utilized for AE grading of severity: Grade 1 (Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 (Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL); Grade 3 (Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 (Life-threatening consequences; urgent intervention indicated); Grade 5 (Death related to AE). Number of NCI grade 3/4/5 Treatment-Emergent Adverse Events (AEs) reported
Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Number of Treatment-emergent Sponsor Identified Immune-related Adverse Events (irAEs)
Number of sponsor-identified irAEs (all grades) reported.
Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Number of Severe (NCI CTCAE Grade 3/4/5) Treatment-emergent Sponsor Identified irAEs
Number of severe treatment-emergent sponsor-identified irAEs reported.
Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Number of Treatment-emergent AEs of Special Interest (AESI)
AEs of special interest (AESI) are AEs required to be monitored, documented, and managed in a pre-specified manner as described in the protocol. Number of treatment-emergent AESI reported.
Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Number of NCI Grade 3/4/5 Treatment-emergent AESI
Number of NCI grade 3/4/5 treatment-emergent AESI reported
Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Number of Participants With Any TEAE Resulting in Death
Number of participants with any TEAE resulting in death reported
Time frame: From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months)
Number of Participants With at Least One Lab Abnormality (NCI-CTCAE All Grades) in Hematology, Electrolytes, Liver, Chemistry
Number of participants with new or worsened laboratory abnormalities (NCI-CTCAE All Grades) reported in Hematology, Electrolytes, Liver, Chemistry; Grade 1 (Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 (Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL); Grade 3 (Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 (Life-threatening consequences; urgent intervention indicated); Grade 5 (Death related to AE).
Time frame: Up to 36 months
Number of Participants Who Developed Dose Limiting Toxicities (DLTs) (Phase 1)
Number of participants who developed dose limiting toxicities (DLTs) in phase 1 reported
Time frame: Baseline to 28 days
Number of Participants Who Developed DLTs (Efficacy Phase)
Time frame: Up to 4 weeks post radiation therapy
Elimination Half-life (t1/2) of Functional Cemiplimab (REGN2810) in Serum
Time frame: Up to 24 months
Trough Concentration (Ctrough) of Functional Cemiplimab (REGN2810) in Serum
Ctrough (trough concentration) of functional cemiplimab in serum reported.
Time frame: Up to Week 16
Peak Concentration (Cmax) of Functional Cemiplimab (REGN2810) in Serum
Cmax (peak concentration) of functional cemiplimab in serum reported.
Time frame: Up to Week 16
Area Under the Concentration-time Curve (AUC) of Functional Cemiplimab (REGN2810) in Serum
Time frame: Up to 24 months
Percentage of Progression-free Survival (PFS) at 12 Months for Participants With Newly Diagnosed HGG (ndHGG)
PFS was defined as the time from randomization to the date of the first documented tumor progression, as determined per Response Assessment in Neuro-Oncology (RANO)/Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria, or death due to any cause.
Time frame: At 12 months
Percentage of Overall Survival (OS) at 12 Months for Participants With ndDIPG and Recurrent HGG (rHGG)
OS was defined as the time from randomization to the date of death due to any cause. A participant who had not died was censored at the last date that participant was documented to be alive. 95% CI is based on Kaplan-Meier method.
Time frame: Up to 12 months
Objective Response Rate (ORR) for Participants Who Have a Confirmed Complete Response (CR) or Partial Response (PR)
ORR was defined as the percentage of participants who have a confirmed complete response (CR) or partial response (PR), as determined per standard criteria between the date of first study treatment and the date of the first objectively documented progression or the date of receiving another anti-cancer systemic therapy, whichever came first. Clopper-Person exact confidence interval
Time frame: Approximately 24 months
Number of Participants With Anti-REGN2810 Antibodies (ADA)
ADA status classified as: Positive; Pre-existing (baseline \[BL\] sample positive \& all post BL ADA titers reported as \< 9-fold BL titer value); Negative (all samples negative); ADA positive: Treatment-boosted (positive result at BL with ≥1 post BL titer result ≥9-fold BL titer value); Treatment-emergent (TE) (negative result or missing result at BL with ≥1 positive post BL result); TE: Persistent (positive result detected in ≥2 consecutive post BL samples separated by ≥ a 12/16-week post BL period with no ADA-negative results in-between, regardless of any missing samples; Indeterminate (positive result in last collection, regardless of any missing samples); Transient (not persistent or indeterminate, regardless of any missing samples)
Time frame: 1st follow-up visit, approximately 25 months
| Milestone | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 5 | 3 | 9 | 5 | 6 | 5 | 12 | 1 | 8 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Not completed | 3 | 5 | 3 | 9 | 5 | 6 | 5 | 11 | 1 | 8 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Death | 1 | 1 | 1 | 4 | 2 | 5 | 3 | 2 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other treatment | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 7 | 0 | 3 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Subject decision | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
TEAEs are AEs that developed or worsened during the on-treatment period and any treatment-related AEs that occur during the post-treatment period but prior to initiation of other anticancer therapy. Number of TEAEs reported.
| Events | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Treatment-emergent Adverse Events (TEAEs) | 19 | 42 | 24 | 56 | 49 | 108 | 102 | 222 | 28 | 175 |
NCI CTCAE version 4.0 was utilized for AE grading of severity: Grade 1 (Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 (Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL); Grade 3 (Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 (Life-threatening consequences; urgent intervention indicated); Grade 5 (Death related to AE). Number of NCI grade 3/4/5 Treatment-Emergent Adverse Events (AEs) reported
| Events | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Severe (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade 3/4/5) TEAEs | 3 | 5 | 0 | 9 | 4 | 25 | 8 | 19 | 4 | 16 |
Number of sponsor-identified irAEs (all grades) reported.
| Events | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Treatment-emergent Sponsor Identified Immune-related Adverse Events (irAEs) | 0 | 1 | 0 | 0 | 0 | 2 | 5 | 9 | 0 | 9 |
Number of severe treatment-emergent sponsor-identified irAEs reported.
| Events | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Severe (NCI CTCAE Grade 3/4/5) Treatment-emergent Sponsor Identified irAEs | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 1 |
AEs of special interest (AESI) are AEs required to be monitored, documented, and managed in a pre-specified manner as described in the protocol. Number of treatment-emergent AESI reported.
| Events | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Treatment-emergent AEs of Special Interest (AESI) | 0 | 0 | 0 | 0 | 1 | 5 | 2 | 4 | 0 | 8 |
Number of NCI grade 3/4/5 treatment-emergent AESI reported
| Events | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of NCI Grade 3/4/5 Treatment-emergent AESI | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 0 | 6 |
Number of participants with any TEAE resulting in death reported
| Participants | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Any TEAE Resulting in Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with new or worsened laboratory abnormalities (NCI-CTCAE All Grades) reported in Hematology, Electrolytes, Liver, Chemistry; Grade 1 (Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 (Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL); Grade 3 (Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 (Life-threatening consequences; urgent intervention indicated); Grade 5 (Death related to AE).
| Participants | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 lab abnormality (All Grades) Hematology | 3 | 4 | 3 | 7 | 3 | 6 | 4 | 11 | 1 | 8 |
| ≥ 1 lab abnormality (All Grades) Electrolytes | 3 | 3 | 0 | 5 | 2 | 6 | 4 | 9 | 1 | 7 |
| ≥ 1 lab abnormality (All Grades) Liver | 1 | 2 | 0 | 5 | 3 | 4 | 5 | 7 | 1 | 5 |
| ≥ 1 lab abnormality (All Grades) Chemistry | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 10 | 1 | 7 |
Number of participants who developed dose limiting toxicities (DLTs) in phase 1 reported
| Participants | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg |
|---|---|---|---|---|---|
| Number of Participants Who Developed Dose Limiting Toxicities (DLTs) (Phase 1) | 0 | 0 | 0 | 0 | 0 |
| Participants | Cohort E Efficacy Phase ndDIPG (DLT AS) | Cohort F Efficacy Phase ndDIPG (DLT AS) | Cohort H Efficacy Phase ndHGG (DLT AS) | Cohort I Efficacy Phase rHGG (DLT AS) | Cohort J Efficacy Phase rHGG (DLT AS) |
|---|---|---|---|---|---|
| Number of Participants Who Developed DLTs (Efficacy Phase) | 1 | 1 | 0 | 0 | 1 |
| milligrams/Liter (mg/L) | Cohort A Phase 1 ST 3mg/kg Q2W (PKAS) | Cohort B Phase 1 ST 3mg/kg Q2W (PKAS) | Cohort C Phase 1 CNS 3mg/kg Q2W (PKAS) | Cohort C Phase 1 CNS 4.5mg/kg Q2W (PKAS) | Cohort D Phase 1 CNS 3mg/kg Q2W (PKAS) | Cohort E Efficacy Phase ndDIPG 4.5mg/kg Q2W (PKAS) | Cohort F Efficacy Phase ndDIPG 3mg/kg Q2W (PKAS) | Cohort H Efficacy Phase ndHGG 3mg/kg Q2W (PKAS) | Cohort I Efficacy Phase rHGG 4.5mg/kg Q2W (PKAS) | Cohort J Efficacy Phase rHGG 3mg/kg Q2W (PKAS) |
|---|---|---|---|---|---|---|---|---|---|---|
| Elimination Half-life (t1/2) of Functional Cemiplimab (REGN2810) in Serum | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Ctrough (trough concentration) of functional cemiplimab in serum reported.
| mg/L | Cohort A Phase 1 ST 3mg/kg Q2W (PKAS) | Cohort B Phase 1 ST 3mg/kg Q2W (PKAS) | Cohort C Phase 1 CNS 3mg/kg Q2W (PKAS) | Cohort D Phase 1 CNS 3mg/kg Q2W (PKAS) | Cohort C Phase 1 CNS 4.5mg/kg Q2W (PKAS) | Cohort F Efficacy Phase ndDIPG 3mg/kg Q2W (PKAS) | Cohort H Efficacy Phase ndHGG 3mg/kg Q2W (PKAS) | Cohort J Efficacy Phase rHGG 3mg/kg Q2W (PKAS) | Cohort E Efficacy Phase ndDIPG 4.5mg/kg Q2W (PKAS) | Cohort I Efficacy Phase rHGG 4.5mg/kg Q2W (PKAS) |
|---|---|---|---|---|---|---|---|---|---|---|
| Ctrough - after 1st dose | 16.7 (14.0 to 16.8) | 23.9 (21.1 to 27.2) | 33.8 (27.9 to 36.5) | 28.5 (19.6 to 42.2) | 48.3 (32.9 to 63.8) | 39.7 (33.9 to 41.9) | 26.0 (17.4 to 36.3) | 36.3 (25.2 to 178) | 35.8 (32.4 to 49.6) | NA (38.5 to 38.5) |
| Ctrough - Week 16 (Cycle 4 Day 1) (4 weeks per cycle) | NA (39.4 to 39.4) | NA (78.6 to 78.6) | — | NA (66.1 to 66.1) | NA (66.1 to 66.1) | 82.4 (65.7 to 104) | 94.3 (84.5 to 247) | 78.5 (57.0 to 134) | 122 (13.1 to 159) | NA (70.0 to 70.0) |
Cmax (peak concentration) of functional cemiplimab in serum reported.
| mg/L | Cohort A Phase 1 ST 3mg/kg Q2W (PKAS) | Cohort B Phase 1 ST 3mg/kg Q2W (PKAS) | Cohort C Phase 1 CNS 3mg/kg Q2W (PKAS) | Cohort D Phase 1 CNS 3mg/kg Q2W (PKAS) | Cohort C Phase 1 CNS 4.5mg/kg Q2W (PKAS) | Cohort F Efficacy Phase ndDIPG 3mg/kg Q2W (PKAS) | Cohort H Efficacy Phase ndHGG 3mg/kg Q2W (PKAS) | Cohort J Efficacy Phase rHGG 3mg/kg Q2W (PKAS) | Cohort E Efficacy Phase ndDIPG 4.5mg/kg Q2W (PKAS) | Cohort I Efficacy Phase rHGG 4.5mg/kg Q2W (PKAS) |
|---|---|---|---|---|---|---|---|---|---|---|
| Cmax - after 1st dose | 58.2 (52.0 to 86.9) | 73.5 (63.4 to 87.9) | 92.2 (87.9 to 101) | 68.3 (60.9 to 101) | 152 (76.0 to 202) | 95.1 (65.5 to 106) | 71.8 (6.41 to 88.0) | 88.8 (69.5 to 124) | 105 (93.7 to 130) | NA (123 to 123) |
| Cmax -Week 16 (Cycle 4 Day 1) (4 weeks per cycle) | NA (122 to 122) | NA (136 to 136) | NA (112 to 112) | NA (112 to 112) | NA (236 to 236) | 221 (164 to 256) | 165 (143 to 200) | 179 (119 to 234) | 209 (99.2 to 297) | NA (225 to 225) |
| mg*hr/L | Cohort A Phase 1 ST 3mg/kg Q2W (PKAS) | Cohort B Phase 1 ST 3mg/kg Q2W (PKAS) | Cohort C Phase 1 CNS 3mg/kg Q2W (PKAS) | Cohort D Phase 1 CNS 3mg/kg Q2W (PKAS) | Cohort C Phase 1 CNS 4.5mg/kg Q2W (PKAS) | Cohort F Efficacy Phase ndDIPG 3mg/kg Q2W (PKAS) | Cohort H Efficacy Phase ndHGG 3mg/kg Q2W (PKAS) | Cohort J Efficacy Phase rHGG 3mg/kg Q2W (PKAS) | Cohort E Efficacy Phase ndDIPG 4.5mg/kg Q2W (PKAS) | Cohort I Efficacy Phase rHGG 4.5mg/kg Q2W (PKAS) |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve (AUC) of Functional Cemiplimab (REGN2810) in Serum | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
PFS was defined as the time from randomization to the date of the first documented tumor progression, as determined per Response Assessment in Neuro-Oncology (RANO)/Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria, or death due to any cause.
| Percentage of Participants | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy |
|---|---|
| Percentage of Progression-free Survival (PFS) at 12 Months for Participants With Newly Diagnosed HGG (ndHGG) | 22.2 (3.4 to 51.3) |
OS was defined as the time from randomization to the date of death due to any cause. A participant who had not died was censored at the last date that participant was documented to be alive. 95% CI is based on Kaplan-Meier method.
| Percentage of Participants | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|
| Percentage of Overall Survival (OS) at 12 Months for Participants With ndDIPG and Recurrent HGG (rHGG) | 0.0 (NA to NA) | 40.0 (5.2 to 75.3) | 0.0 (NA to NA) | 35.7 (5.2 to 69.9) |
ORR was defined as the percentage of participants who have a confirmed complete response (CR) or partial response (PR), as determined per standard criteria between the date of first study treatment and the date of the first objectively documented progression or the date of receiving another anti-cancer systemic therapy, whichever came first. Clopper-Person exact confidence interval
| Percentage of Participants | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | Newly Diagnosed HGG (ndHGG) (Efficacy Phase) | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) for Participants Who Have a Confirmed Complete Response (CR) or Partial Response (PR) | 0 (0.0 to 70.8) | 0 (0.0 to 52.2) | 0 (0.0 to 70.8) | 0 (0.0 to 33.6) | 0 (0.0 to 52.2) | 0 (0.0 to 45.9) | 0 (0.0 to 52.2) | 8.3 (0.2 to 38.5) | 0 (0.0 to 97.5) | 0 (0.0 to 36.9) |
ADA status classified as: Positive; Pre-existing (baseline \[BL\] sample positive \& all post BL ADA titers reported as \< 9-fold BL titer value); Negative (all samples negative); ADA positive: Treatment-boosted (positive result at BL with ≥1 post BL titer result ≥9-fold BL titer value); Treatment-emergent (TE) (negative result or missing result at BL with ≥1 positive post BL result); TE: Persistent (positive result detected in ≥2 consecutive post BL samples separated by ≥ a 12/16-week post BL period with no ADA-negative results in-between, regardless of any missing samples; Indeterminate (positive result in last collection, regardless of any missing samples); Transient (not persistent or indeterminate, regardless of any missing samples)
| Participants | Phase 1: 3mg/kg Q2W (AAS) | Phase 1: 4.5mg/kg Q2W (AAS) | Efficacy Phase: 3mg/kg Q2W (AAS) | Efficacy Phase: 4.5mg/kg Q2W (AAS) |
|---|---|---|---|---|
| Negative | 16 | 5 | 17 | 6 |
| Pre-existing immunoreactivity | 0 | 0 | 1 | 0 |
| Treatment-emergent (TE) response | 0 | 0 | 1 | 1 |
Collected over From first dose of study drug up to 90 days after the last dose of study treatment (up to 36 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOLID TUMOR < 12 yr REGN2810 3mg/kg | 2/3 (66.7%) | 0/3 (0%) | 3/3 (100%) |
| SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | 4/5 (80%) | 0/5 (0%) | 5/5 (100%) |
| CNS TUMOR <12 yr REGN2810 3mg/kg | 2/3 (66.7%) | 0/3 (0%) | 2/3 (66.7%) |
| CNS TUMOR <12 yr REGN2810 4.5mg/kg | 8/9 (88.9%) | 3/9 (33.3%) | 8/9 (88.9%) |
| CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | 3/5 (60%) | 0/5 (0%) | 4/5 (80%) |
| ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | 6/6 (100%) | 3/6 (50%) | 6/6 (100%) |
| ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | 4/5 (80%) | 3/5 (60%) | 5/5 (100%) |
| ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | 7/12 (58.3%) | 7/12 (58.3%) | 12/12 (100%) |
| rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation | 5/8 (62.5%) | 5/8 (62.5%) | 8/8 (100%) |
| Event | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| Tumour pseudoprogressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 2/6 | 0/5 | 1/12 | 0/1 | 0/8 |
| Alanine aminotransferase increasedInvestigations | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 0/6 | 1/5 | 1/12 | 0/1 | 0/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 0/6 | 1/5 | 0/12 | 0/1 | 1/8 |
| HeadacheNervous system disorders | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 0/6 | 1/5 | 1/12 | 0/1 | 1/8 |
| HydrocephalusNervous system disorders | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 0/6 | 1/5 | 0/12 | 0/1 | 1/8 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 1/6 | 0/5 | 0/12 | 0/1 | 0/8 |
| Device related infectionInfections and infestations | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 1/6 | 0/5 | 0/12 | 0/1 | 0/8 |
| ConstipationGastrointestinal disorders | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 1/6 | 0/5 | 0/12 | 0/1 | 0/8 |
| Wound dehiscenceInjury, poisoning and procedural complications | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 1/6 | 0/5 | 0/12 | 0/1 | 0/8 |
| Weight decreasedInvestigations | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 1/6 | 0/5 | 0/12 | 0/1 | 0/8 |
| Event | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation |
|---|---|---|---|---|---|---|---|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 1/3 | 0/5 | 0/3 | 3/9 | 1/5 | 0/6 | 2/5 | 2/12 | 1/1 | 1/8 |
| HypophosphataemiaMetabolism and nutrition disorders | 1/3 | 0/5 | 0/3 | 1/9 | 1/5 | 1/6 | 0/5 | 4/12 | 1/1 | 1/8 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 0/6 | 2/5 | 2/12 | 1/1 | 1/8 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 0/3 | 1/5 | 0/3 | 0/9 | 0/5 | 0/6 | 1/5 | 1/12 | 1/1 | 1/8 |
| HypocalcaemiaMetabolism and nutrition disorders | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 0/6 | 1/5 | 1/12 | 1/1 | 2/8 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 0/6 | 1/5 | 0/12 | 1/1 | 0/8 |
| HyponatraemiaMetabolism and nutrition disorders | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 1/6 | 0/5 | 2/12 | 1/1 | 0/8 |
| Abdominal pain upperGastrointestinal disorders | 0/3 | 0/5 | 0/3 | 0/9 | 0/5 | 0/6 | 0/5 | 1/12 | 1/1 | 0/8 |
| FatigueGeneral disorders | 1/3 | 1/5 | 1/3 | 2/9 | 4/5 | 1/6 | 2/5 | 6/12 | 1/1 | 6/8 |
| PyrexiaGeneral disorders | 1/3 | 1/5 | 1/3 | 0/9 | 1/5 | 1/6 | 1/5 | 3/12 | 1/1 | 1/8 |
| Age, Continuous(years) | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 7.0 ± 5.29 | 13.4 ± 1.95 | 7.7 ± 1.53 | 7.1 ± 2.26 | 15.0 ± 1.00 | 4.8 ± 1.83 | 15.4 ± 2.41 | 16.4 ± 3.63 | 8.0 ± 0 | 16.3 ± 3.01 | 12.1 ± 5.23 |
| Sex: Female, Male(Participants) | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 1 | 4 | 2 | 4 | 4 | 4 | 1 | 2 | 25 |
| Male | 2 | 3 | 2 | 5 | 3 | 2 | 1 | 8 | 0 | 6 | 32 |
| Ethnicity (NIH/OMB)(Participants) | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 0 | 2 | 3 | 3 | 1 | 5 | 1 | 3 | 21 |
| Not Hispanic or Latino | 3 | 2 | 3 | 7 | 2 | 1 | 4 | 6 | 0 | 5 | 33 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | SOLID TUMOR < 12 yr REGN2810 3mg/kg | SOLID TUMOR 12 to <18 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 3mg/kg | CNS TUMOR <12 yr REGN2810 4.5mg/kg | CNS TUMOR 12 to <18 yr REGN2810 3mg/kg | ndDIPG <12 yr REGN2810 4.5mg/kg + Radiotherapy | ndDIPG >=12 yr REGN2810 3mg/kg + Radiotherapy | ndHGG >=12 yr REGN2810 3mg/kg + Radiotherapy | rHGG <12 yr REGN2810 4.5mg/kg + Re-Irradiation | rHGG >= 12 yr REGN2810 3mg/kg + Re-Irradiation | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 3 | 3 | 3 | 5 | 3 | 2 | 4 | 12 | 1 | 4 | 40 |
| Black or African American | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 2 | 6 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Unknown | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 4 |
| Not reported | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in May 2023, 55 months.
Results were first posted in Oct 2024, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab
Diffuse Intrinsic Pontine Glioma →